董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Hastings | 男 | Director | 62 | 8.74万美元 | 未持股 | 2023-05-01 |
| David Angulo | 男 | Chief Executive Officer, President and Director | 58 | 116.88万美元 | 未持股 | 2023-05-01 |
| Philippe Tinmouth | 男 | Director | 59 | 7.84万美元 | 未持股 | 2023-05-01 |
| Armando Anido | 男 | Director | 65 | 8.19万美元 | 未持股 | 2023-05-01 |
| Steven C. Gilman | 男 | Director | 71 | 8.94万美元 | 未持股 | 2023-05-01 |
| Ann F. Hanham | 女 | Director | 70 | 8.84万美元 | 未持股 | 2023-05-01 |
| Guy Macdonald | 男 | Chairman of the Board, Director | 63 | 11.19万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Angulo | 男 | Chief Executive Officer, President and Director | 58 | 116.88万美元 | 未持股 | 2023-05-01 |
| Scott Sukenick | 男 | General Counsel | 45 | 97.68万美元 | 未持股 | 2023-05-01 |
| Ivor Macleod | 男 | Chief Financial Officer | 62 | 未披露 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- David Hastings
-
David Hastings，2015年2月起，担任高级副总裁、首席财务官。加入之前，2003-2014，他是制药公司Incyte Corporation的执行副总裁、首席财务官；2000年2月至2003年9月，担任ArQule, Inc.的副总裁、首席财务官、财务总管。此前，他是Genzyme, Inc.的副总裁、企业财务总监，负责财务部门的管理。此前，他担任制药公司Sepracor, Inc.（现Sunovion Pharmaceuticals, Inc.）的财务总监，主要负责内部和外部报告。他是一名注册会计师，在University of Vermont获得经济学士学位。
David Hastings,joined Scynexis, Inc. Board on September 24, 2015. Mr. Hastings has served as the Chief Financial Officer at Arbutus Biopharma Corp. (Nasdaq: ABUS), a publicly-traded biopharmaceutical company, since June 2018. He has served as a member of the board of directors since January 2018 and has served as chairman of the audit committee of VBL Therapeutics (Nasdaq: VBLT) since April 2018. From February 2015 to June 2017, Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation, a publicly-traded medical technology company, and from July 2016 to June 2017, Mr. Hastings also served as Unilife's Chief Accounting Officer and Treasurer. Prior to joining Unilife, Mr. Hastings served as Executive Vice President and Chief Financial Officer at Incyte Corporation, a publicly-traded biopharmaceutical company, from October 2003 to October 2014. From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule, Inc. Mr. Hastings previously served on the board of directors of Entasis Therapeutics Inc. Mr. Hastings received his B.A. in Economics at the University of Vermont. - David Hastings，2015年2月起，担任高级副总裁、首席财务官。加入之前，2003-2014，他是制药公司Incyte Corporation的执行副总裁、首席财务官；2000年2月至2003年9月，担任ArQule, Inc.的副总裁、首席财务官、财务总管。此前，他是Genzyme, Inc.的副总裁、企业财务总监，负责财务部门的管理。此前，他担任制药公司Sepracor, Inc.（现Sunovion Pharmaceuticals, Inc.）的财务总监，主要负责内部和外部报告。他是一名注册会计师，在University of Vermont获得经济学士学位。
- David Hastings,joined Scynexis, Inc. Board on September 24, 2015. Mr. Hastings has served as the Chief Financial Officer at Arbutus Biopharma Corp. (Nasdaq: ABUS), a publicly-traded biopharmaceutical company, since June 2018. He has served as a member of the board of directors since January 2018 and has served as chairman of the audit committee of VBL Therapeutics (Nasdaq: VBLT) since April 2018. From February 2015 to June 2017, Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation, a publicly-traded medical technology company, and from July 2016 to June 2017, Mr. Hastings also served as Unilife's Chief Accounting Officer and Treasurer. Prior to joining Unilife, Mr. Hastings served as Executive Vice President and Chief Financial Officer at Incyte Corporation, a publicly-traded biopharmaceutical company, from October 2003 to October 2014. From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule, Inc. Mr. Hastings previously served on the board of directors of Entasis Therapeutics Inc. Mr. Hastings received his B.A. in Economics at the University of Vermont.
- David Angulo
-
David Angulo，曾一直担任Scynexis, Inc.的首席医疗官（2015年6月以来）。2010年10月至2015年5月，他曾担任Brickell Biotech, Inc.的研发副总裁，在那里他曾负责定义和执行所有产品的整体药物开发策略。加入Brickell公司之前，他曾担任Stiefel Laboratories, Inc.（GSK公司）的多种高级职务，包括临床和医疗部门主管（从2006年4月到2010年10月）。1998年至2006年，他也曾负责Schering-Plough Research Institute的抗感染区域的一些开发项目，也曾担任一个儿科医院的传染性疾病的医生。他持有the Universidad de Guadalajara（位于墨西哥）的医疗学位，以及儿科和传染病研究生学位。
David Angulo,has served as a member of Scynexis, Inc. Board and as Scynexis, Inc. Chief Executive Officer since January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases. - David Angulo，曾一直担任Scynexis, Inc.的首席医疗官（2015年6月以来）。2010年10月至2015年5月，他曾担任Brickell Biotech, Inc.的研发副总裁，在那里他曾负责定义和执行所有产品的整体药物开发策略。加入Brickell公司之前，他曾担任Stiefel Laboratories, Inc.（GSK公司）的多种高级职务，包括临床和医疗部门主管（从2006年4月到2010年10月）。1998年至2006年，他也曾负责Schering-Plough Research Institute的抗感染区域的一些开发项目，也曾担任一个儿科医院的传染性疾病的医生。他持有the Universidad de Guadalajara（位于墨西哥）的医疗学位，以及儿科和传染病研究生学位。
- David Angulo,has served as a member of Scynexis, Inc. Board and as Scynexis, Inc. Chief Executive Officer since January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.
- Philippe Tinmouth
-
Philippe Tinmouth，2019年12月13日加入Scynexis, Inc.董事会。Tinmouth先生自2022年12月起担任生物技术公司Mammoth Biosciences，Inc.的首席业务和战略官。从2021年11月到2022年12月，Tinmouth先生担任Pardes Biosciences（纳斯达克：PRDS）的首席业务和战略官，该公司是一家上市生物制药公司。从2002年10月到2020年3月退休，Tinmouth先生曾在福泰制药（纳斯达克：VRTX）担任多个职位，该公司是一家上市生物制药公司，最近自2013年7月起担任副总裁兼业务发展与联盟管理主管。从1997年到2002年，廷茅斯先生在贝恩公司担任过多个职位，最近担任波士顿办事处的高级经理，在那里他为《财富》50强制药公司和较小的生物技术公司的增长战略提供建议。Tinmouth先生通过哈佛创新实验室（Harvard iLab）和加拿大技术加速器担任生物技术初创企业的导师和顾问。Tinmouth先生拥有哈佛商学院工商管理硕士学位和加拿大女王大学机械工程学荣誉学士学位。
Philippe Tinmouth,joined Scynexis, Inc. Board on December 13, 2019. Mr. Tinmouth has served as Chief Business and Strategy Officer of Mammoth Biosciences, Inc., a biotechnology company, since December 2022. From November 2021 through December 2022, Mr. Tinmouth served as Chief Business and Strategy Officer of Pardes Biosciences (Nasdaq: PRDS), a publicly-traded biopharmaceutical company. From October 2002 through his retirement in March 2020, Mr. Tinmouth served in various positions at Vertex Pharmaceuticals (Nasdaq: VRTX), a publicly traded biopharmaceutical company, most recently serving as Vice President and Head of Business Development & Alliance Management since July 2013. From 1997 to 2002, Mr. Tinmouth held various positions at Bain & Company, most recently serving as a Senior Manager in the Boston office, where he advised both Fortune 50 pharmaceutical companies and smaller biotechnology companies on growth strategies. Mr. Tinmouth has served as a mentor and advisor to biotech start-ups through both the Harvard Innovation Lab (Harvard iLab) and the Canadian Technology Accelerator. Mr. Tinmouth holds a Master's Degree in Business Administration from Harvard Business School and a Bachelor's Degree with Honors in Mechanical Engineering from Queen's University in Canada. - Philippe Tinmouth，2019年12月13日加入Scynexis, Inc.董事会。Tinmouth先生自2022年12月起担任生物技术公司Mammoth Biosciences，Inc.的首席业务和战略官。从2021年11月到2022年12月，Tinmouth先生担任Pardes Biosciences（纳斯达克：PRDS）的首席业务和战略官，该公司是一家上市生物制药公司。从2002年10月到2020年3月退休，Tinmouth先生曾在福泰制药（纳斯达克：VRTX）担任多个职位，该公司是一家上市生物制药公司，最近自2013年7月起担任副总裁兼业务发展与联盟管理主管。从1997年到2002年，廷茅斯先生在贝恩公司担任过多个职位，最近担任波士顿办事处的高级经理，在那里他为《财富》50强制药公司和较小的生物技术公司的增长战略提供建议。Tinmouth先生通过哈佛创新实验室（Harvard iLab）和加拿大技术加速器担任生物技术初创企业的导师和顾问。Tinmouth先生拥有哈佛商学院工商管理硕士学位和加拿大女王大学机械工程学荣誉学士学位。
- Philippe Tinmouth,joined Scynexis, Inc. Board on December 13, 2019. Mr. Tinmouth has served as Chief Business and Strategy Officer of Mammoth Biosciences, Inc., a biotechnology company, since December 2022. From November 2021 through December 2022, Mr. Tinmouth served as Chief Business and Strategy Officer of Pardes Biosciences (Nasdaq: PRDS), a publicly-traded biopharmaceutical company. From October 2002 through his retirement in March 2020, Mr. Tinmouth served in various positions at Vertex Pharmaceuticals (Nasdaq: VRTX), a publicly traded biopharmaceutical company, most recently serving as Vice President and Head of Business Development & Alliance Management since July 2013. From 1997 to 2002, Mr. Tinmouth held various positions at Bain & Company, most recently serving as a Senior Manager in the Boston office, where he advised both Fortune 50 pharmaceutical companies and smaller biotechnology companies on growth strategies. Mr. Tinmouth has served as a mentor and advisor to biotech start-ups through both the Harvard Innovation Lab (Harvard iLab) and the Canadian Technology Accelerator. Mr. Tinmouth holds a Master's Degree in Business Administration from Harvard Business School and a Bachelor's Degree with Honors in Mechanical Engineering from Queen's University in Canada.
- Armando Anido
-
Armando Anido担任AUXILIUM制药公司（Auxilium Pharmaceuticals, Inc.）首席执行官和总裁，这是一家公开上市的专业生物制药公司，专注于开发和营销泌尿科，内分泌科，骨科，选择性初级保健医疗等方面的产品。在成为AUXILIUM首席执行官之前，1999至2006年Anido先生是MedImmune公司（MedImmune, Inc）的执行副总裁，销售和市场营销员，负责其投资组合的全球商业化。他还担任了执行委员会和产品开发委员会委员。在MedImmune公司（MedImmune, Inc）之前，1995年至1999年Anido先生加盟GlaxoWellcome公司（GlaxoWellcome, Inc）担任HIV市场董事之后，他在该公司担任中枢神经系统营销副总裁。1989年至1995年Anido先生受雇于莱德利实验室（Lederle Labs），并扮演各种商业角色，最终担任抗感染药物副总裁。 Anido先生担任AUXILIUM医药公司（Auxilium Pharmaceuticals, Inc）的董事会董事，Anido先生获得了西弗吉尼亚大学（West Virginia University）药剂业学士学位及市场和金融的MBA学位。
Armando Anido,joined Scynexis, Inc. Board on January 21, 2019. Mr. Anido has served as Chairman of the board of directors and Chief Executive Officer of Zynerba Pharmaceuticals (Nasdaq: ZYNE), a publicly-traded biopharmaceutical company, since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO and a director of NuPathe Inc., a publicly-traded pharmaceutical company, which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity, the first transdermal patch for migraine, to pre-launch before the company's acquisition by Teva. Prior to NuPathe he served as President, CEO and a director of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He is currently a member of the Board of Directors of Altamira Therapeutics Ltd. (Nasdaq: CYTO) (formerly Auris Medical Holding AG), and he previously was a member of the Board of Directors of Life Science PA, of Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011, and of Aviragen Therapeutics, Inc. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University. - Armando Anido担任AUXILIUM制药公司（Auxilium Pharmaceuticals, Inc.）首席执行官和总裁，这是一家公开上市的专业生物制药公司，专注于开发和营销泌尿科，内分泌科，骨科，选择性初级保健医疗等方面的产品。在成为AUXILIUM首席执行官之前，1999至2006年Anido先生是MedImmune公司（MedImmune, Inc）的执行副总裁，销售和市场营销员，负责其投资组合的全球商业化。他还担任了执行委员会和产品开发委员会委员。在MedImmune公司（MedImmune, Inc）之前，1995年至1999年Anido先生加盟GlaxoWellcome公司（GlaxoWellcome, Inc）担任HIV市场董事之后，他在该公司担任中枢神经系统营销副总裁。1989年至1995年Anido先生受雇于莱德利实验室（Lederle Labs），并扮演各种商业角色，最终担任抗感染药物副总裁。 Anido先生担任AUXILIUM医药公司（Auxilium Pharmaceuticals, Inc）的董事会董事，Anido先生获得了西弗吉尼亚大学（West Virginia University）药剂业学士学位及市场和金融的MBA学位。
- Armando Anido,joined Scynexis, Inc. Board on January 21, 2019. Mr. Anido has served as Chairman of the board of directors and Chief Executive Officer of Zynerba Pharmaceuticals (Nasdaq: ZYNE), a publicly-traded biopharmaceutical company, since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO and a director of NuPathe Inc., a publicly-traded pharmaceutical company, which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity, the first transdermal patch for migraine, to pre-launch before the company's acquisition by Teva. Prior to NuPathe he served as President, CEO and a director of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He is currently a member of the Board of Directors of Altamira Therapeutics Ltd. (Nasdaq: CYTO) (formerly Auris Medical Holding AG), and he previously was a member of the Board of Directors of Life Science PA, of Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011, and of Aviragen Therapeutics, Inc. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.
- Steven C. Gilman
-
Steven C. Gilman，2010年9月开始，他就是研究开发部的执行副总裁和首席战略官。在这之前，2008年2月到2010年9月，他是发现和临床发展部的高级副总裁和首席战略官。2007年4月到2008年2月，他是ActivBiotics公司，（一家私营生物制药公司）的董事会主席和首席执行官。2004年3月到2007年4月，他是ActivBiotics公司的董事会成员、总裁和首席执行官。他任职于马萨诸塞州生物技术委员会和inhibikase疗法公司，（一家强调提高临床研究质量和改善患者安全的非营利组织）。另外，他任职于科学领导和美国药物研究和制造商协会 ，任职于东北大学医药资讯委员会和宾夕法尼亚州州立大学生物技术咨询委员会。
Steven C. Gilman,joined Scynexis, Inc. Board on February 25, 2015. Prior to his retirement in April 2019, Dr. Gilman served as the Chairman of the board of directors and President and Chief Executive Officer of ContraFect Corporation (Nasdaq: CFRX), a publicly-traded biotechnology company, since May 2015. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, a publicly-traded biopharmaceutical company, until its acquisition by Merck & Co in January 2015. Prior to joining Cubist, Dr. Gilman served as chairman of the board of directors and CEO of ActivBiotics from March 2004 to October 2007. Prior to ActivBiotics, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., from October 2000 to March 2004 where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently serves on the board of directors of Vericel Corporation (Nasdaq: VCEL), Akebia Therapeutics, Inc. (Nasdaq: AKBA), and ContraFect Corporation (Nasdaq: CFRX), and previously served on the board of directors of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA). Dr. Gilman received his Ph.D. and MS degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinical and Research Foundation and received a B.A. in microbiology from Miami University of Ohio. - Steven C. Gilman，2010年9月开始，他就是研究开发部的执行副总裁和首席战略官。在这之前，2008年2月到2010年9月，他是发现和临床发展部的高级副总裁和首席战略官。2007年4月到2008年2月，他是ActivBiotics公司，（一家私营生物制药公司）的董事会主席和首席执行官。2004年3月到2007年4月，他是ActivBiotics公司的董事会成员、总裁和首席执行官。他任职于马萨诸塞州生物技术委员会和inhibikase疗法公司，（一家强调提高临床研究质量和改善患者安全的非营利组织）。另外，他任职于科学领导和美国药物研究和制造商协会 ，任职于东北大学医药资讯委员会和宾夕法尼亚州州立大学生物技术咨询委员会。
- Steven C. Gilman,joined Scynexis, Inc. Board on February 25, 2015. Prior to his retirement in April 2019, Dr. Gilman served as the Chairman of the board of directors and President and Chief Executive Officer of ContraFect Corporation (Nasdaq: CFRX), a publicly-traded biotechnology company, since May 2015. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, a publicly-traded biopharmaceutical company, until its acquisition by Merck & Co in January 2015. Prior to joining Cubist, Dr. Gilman served as chairman of the board of directors and CEO of ActivBiotics from March 2004 to October 2007. Prior to ActivBiotics, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., from October 2000 to March 2004 where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently serves on the board of directors of Vericel Corporation (Nasdaq: VCEL), Akebia Therapeutics, Inc. (Nasdaq: AKBA), and ContraFect Corporation (Nasdaq: CFRX), and previously served on the board of directors of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA). Dr. Gilman received his Ph.D. and MS degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinical and Research Foundation and received a B.A. in microbiology from Miami University of Ohio.
- Ann F. Hanham
-
Ann F. Hanham，2004年11月起，成为董事会成员；2000年2月，加入Burrill & Company（风险资本和商业银行公司）；2002年至2013年，担任行政董事；2001年5月至2006年9月，在BioMimetic Therapeutics（生物制药公司）担任董事；2009年3月至2011年4月，是Biotie Therapies（药物开发公司）董事；2005年9月至2006年8月，是Targacept（生物制药公司）董事。获有多伦多大学学士学位、西蒙弗雷泽大学硕士学位以及英属哥伦比亚大学医学博士学位。
Ann F. Hanham,has served as a member of Scynexis, Inc. Board since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management, a privately-held life-sciences venture capital fund, in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. She serves as a member of the board of directors of HTG Molecular Diagnostics Inc. (Nasdaq: HTGM) and previously served as a member of the boards of directors of Acusphere Inc. (OTCMKTS: ACUS), Biomimetic Therapeutics Inc. (Nasdaq: BMTI), Biotie Therapies Corp. (Nordic List: BTH1V), Immunicon Corp. (Nasdaq: IMMC), Targacept Inc. (Nasdaq: TRGT), TLC (GreTai Sec M: 1452:TT) and Endocyte, Inc. (Nasdaq: ECYT). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. - Ann F. Hanham，2004年11月起，成为董事会成员；2000年2月，加入Burrill & Company（风险资本和商业银行公司）；2002年至2013年，担任行政董事；2001年5月至2006年9月，在BioMimetic Therapeutics（生物制药公司）担任董事；2009年3月至2011年4月，是Biotie Therapies（药物开发公司）董事；2005年9月至2006年8月，是Targacept（生物制药公司）董事。获有多伦多大学学士学位、西蒙弗雷泽大学硕士学位以及英属哥伦比亚大学医学博士学位。
- Ann F. Hanham,has served as a member of Scynexis, Inc. Board since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management, a privately-held life-sciences venture capital fund, in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. She serves as a member of the board of directors of HTG Molecular Diagnostics Inc. (Nasdaq: HTGM) and previously served as a member of the boards of directors of Acusphere Inc. (OTCMKTS: ACUS), Biomimetic Therapeutics Inc. (Nasdaq: BMTI), Biotie Therapies Corp. (Nordic List: BTH1V), Immunicon Corp. (Nasdaq: IMMC), Targacept Inc. (Nasdaq: TRGT), TLC (GreTai Sec M: 1452:TT) and Endocyte, Inc. (Nasdaq: ECYT). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.
- Guy Macdonald
-
Guy Macdonald，2008年1月起，他担任Scynexis, Inc.总裁、首席执行官和董事会成员。2003年8月至2008年1月，他担任生物制药公司艾德尼克斯制药有限公司（Idenix Pharmaceuticals, Inc.）的运营执行副总裁。加入Idenix之前，1981至2003年，他在制药公司默克公司（Merck & Co., Inc.）担任多职，最近担任抗感染和医院产品副总裁。他目前是私营公司Spring Bank Pharmaceuticals, Inc.的董事会主席。他在苏格兰邓迪大学（Dundee University）获得生物化学荣誉学位。
Guy Macdonald,has served as a member of Scynexis, Inc. Board since November 2014. Mr. Macdonald served as a member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a publicly-traded biopharmaceutical company, from January 2008 to July 2020, in addition to serving as its President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc., most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland. - Guy Macdonald，2008年1月起，他担任Scynexis, Inc.总裁、首席执行官和董事会成员。2003年8月至2008年1月，他担任生物制药公司艾德尼克斯制药有限公司（Idenix Pharmaceuticals, Inc.）的运营执行副总裁。加入Idenix之前，1981至2003年，他在制药公司默克公司（Merck & Co., Inc.）担任多职，最近担任抗感染和医院产品副总裁。他目前是私营公司Spring Bank Pharmaceuticals, Inc.的董事会主席。他在苏格兰邓迪大学（Dundee University）获得生物化学荣誉学位。
- Guy Macdonald,has served as a member of Scynexis, Inc. Board since November 2014. Mr. Macdonald served as a member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a publicly-traded biopharmaceutical company, from January 2008 to July 2020, in addition to serving as its President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc., most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland.
高管简历
中英对照 | 中文 | 英文- David Angulo
David Angulo，曾一直担任Scynexis, Inc.的首席医疗官（2015年6月以来）。2010年10月至2015年5月，他曾担任Brickell Biotech, Inc.的研发副总裁，在那里他曾负责定义和执行所有产品的整体药物开发策略。加入Brickell公司之前，他曾担任Stiefel Laboratories, Inc.（GSK公司）的多种高级职务，包括临床和医疗部门主管（从2006年4月到2010年10月）。1998年至2006年，他也曾负责Schering-Plough Research Institute的抗感染区域的一些开发项目，也曾担任一个儿科医院的传染性疾病的医生。他持有the Universidad de Guadalajara（位于墨西哥）的医疗学位，以及儿科和传染病研究生学位。
David Angulo,has served as a member of Scynexis, Inc. Board and as Scynexis, Inc. Chief Executive Officer since January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.- David Angulo，曾一直担任Scynexis, Inc.的首席医疗官（2015年6月以来）。2010年10月至2015年5月，他曾担任Brickell Biotech, Inc.的研发副总裁，在那里他曾负责定义和执行所有产品的整体药物开发策略。加入Brickell公司之前，他曾担任Stiefel Laboratories, Inc.（GSK公司）的多种高级职务，包括临床和医疗部门主管（从2006年4月到2010年10月）。1998年至2006年，他也曾负责Schering-Plough Research Institute的抗感染区域的一些开发项目，也曾担任一个儿科医院的传染性疾病的医生。他持有the Universidad de Guadalajara（位于墨西哥）的医疗学位，以及儿科和传染病研究生学位。
- David Angulo,has served as a member of Scynexis, Inc. Board and as Scynexis, Inc. Chief Executive Officer since January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc. Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.
- Scott Sukenick
Scott Sukenick自2017年11月起担任我们的总法律顾问。在加入Scynexis之前，Sukenick先生于2012年10月至2017年11月担任律师事务所Cooley LLP的高级律师，在那里他专注于生命科学诉讼和战略知识产权管理。从2010年9月到2012年10月，他曾任职Patterson Belknap Webb&Tyler公司，在那里他主要代表制药和医疗设备公司进行专利诉讼。他的职业生涯始于2006年9月至2010年9月，任职于Simpson Thacher&Bartlett LLP，专注于复杂的商业诉讼和知识产权交易事务。Sukenick先生是一名注册专利律师。他在杜克大学（Duke University）获得生物学学士学位和化学学士学位，在哈佛大学（Harvard University）获得法学博士学位。
Scott Sukenick,has served as Scynexis, Inc. General Counsel since November 2017. Prior to joining SCYNEXIS, Mr. Sukenick was a Senior Associate at the law firm Cooley LLP from October 2012 to November 2017, where he focused on life sciences litigation and strategic intellectual property management. From September 2010 to October 2012, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career and worked at Simpson Thacher & Bartlett LLP from September 2006 to September 2010, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.- Scott Sukenick自2017年11月起担任我们的总法律顾问。在加入Scynexis之前，Sukenick先生于2012年10月至2017年11月担任律师事务所Cooley LLP的高级律师，在那里他专注于生命科学诉讼和战略知识产权管理。从2010年9月到2012年10月，他曾任职Patterson Belknap Webb&Tyler公司，在那里他主要代表制药和医疗设备公司进行专利诉讼。他的职业生涯始于2006年9月至2010年9月，任职于Simpson Thacher&Bartlett LLP，专注于复杂的商业诉讼和知识产权交易事务。Sukenick先生是一名注册专利律师。他在杜克大学（Duke University）获得生物学学士学位和化学学士学位，在哈佛大学（Harvard University）获得法学博士学位。
- Scott Sukenick,has served as Scynexis, Inc. General Counsel since November 2017. Prior to joining SCYNEXIS, Mr. Sukenick was a Senior Associate at the law firm Cooley LLP from October 2012 to November 2017, where he focused on life sciences litigation and strategic intellectual property management. From September 2010 to October 2012, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career and worked at Simpson Thacher & Bartlett LLP from September 2006 to September 2010, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.
- Ivor Macleod
Ivor Macleod，自2022年10月起担任Scynexis, Inc.首席财务官。在加入SCYNEXIS之前，Macleod先生于2020年1月至2022年10月在Athersys, Inc.（一家专注于再生医学的临床阶段生物技术公司）担任首席财务官，负责财务、会计、投资者关系和企业传播部门。在此之前，他曾于2015年至2018年担任卫材公司（Eisai Co.，Ltd.）的美国制药子公司卫材公司（Eisai Inc.）的首席财务官和首席合规官，卫材公司是一家日本以研究为基础的人类保健公司，在全球范围内发现、开发和营销产品，在此期间，他负责财务、会计和商业分析小组，并监督企业和商业合规。在加入卫材之前，Macleod先生曾于2012年至2015年在默克制药公司（一家全球性的医疗保健公司）担任财务副总裁– 默沙东研究实验室，该公司通过其处方药、疫苗、生物疗法和动物保健产品提供创新的健康解决方案。在加入默沙东之前，Macleod先生于1998年至2012年在跨国医疗保健公司F. Hoffmann-La Roche，Inc.任职，担任过多个职务，包括2000年至2011年担任北美首席财务官以及2010年至2011年担任总经理。麦克劳德先生获得了苏格兰圣安德鲁斯大学的理学学士学位和亚利桑那大学的工商管理硕士学位。Macleod先生是一名注册会计师，在弗吉尼亚州获得执照。
Ivor Macleod,has served as Scynexis, Inc. Chief Financial Officer since October 2022. Prior to joining SCYNEXIS, Mr. Macleod served as Chief Financial Officer at Athersys, Inc., a clinical stage biotechnology company focused on regenerative medicine, from January 2020 to October 2022, in which role he was responsible for the Finance, Accounting, Investor Relations, and Corporate Communications departments. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a Japanese research-based human health care company that discovers, develops and markets products globally, from 2015 to 2018, in which role he was responsible for the Finance, Accounting, and Commercial Analytics groups as well as overseeing both Corporate and Commercial Compliance. Prior to joining Eisai, Mr. Macleod served as Vice President Finance – Merck Research Labs at Merck & Co., Inc., a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, from 2012 to 2015. Before joining Merck, Mr. Macleod served from 1998 to 2012 at F. Hoffmann-La Roche, Inc., a multinational health care company, in various roles, including as North American Chief Financial Officer from 2000 to 2011 as well as General Manager from 2010 to 2011. Mr. Macleod received his B.Sc. from St. Andrews University in Scotland and his M.B.A. from the University of Arizona. Mr. Macleod is a Certified Public Accountant licensed in Virginia.- Ivor Macleod，自2022年10月起担任Scynexis, Inc.首席财务官。在加入SCYNEXIS之前，Macleod先生于2020年1月至2022年10月在Athersys, Inc.（一家专注于再生医学的临床阶段生物技术公司）担任首席财务官，负责财务、会计、投资者关系和企业传播部门。在此之前，他曾于2015年至2018年担任卫材公司（Eisai Co.，Ltd.）的美国制药子公司卫材公司（Eisai Inc.）的首席财务官和首席合规官，卫材公司是一家日本以研究为基础的人类保健公司，在全球范围内发现、开发和营销产品，在此期间，他负责财务、会计和商业分析小组，并监督企业和商业合规。在加入卫材之前，Macleod先生曾于2012年至2015年在默克制药公司（一家全球性的医疗保健公司）担任财务副总裁– 默沙东研究实验室，该公司通过其处方药、疫苗、生物疗法和动物保健产品提供创新的健康解决方案。在加入默沙东之前，Macleod先生于1998年至2012年在跨国医疗保健公司F. Hoffmann-La Roche，Inc.任职，担任过多个职务，包括2000年至2011年担任北美首席财务官以及2010年至2011年担任总经理。麦克劳德先生获得了苏格兰圣安德鲁斯大学的理学学士学位和亚利桑那大学的工商管理硕士学位。Macleod先生是一名注册会计师，在弗吉尼亚州获得执照。
- Ivor Macleod,has served as Scynexis, Inc. Chief Financial Officer since October 2022. Prior to joining SCYNEXIS, Mr. Macleod served as Chief Financial Officer at Athersys, Inc., a clinical stage biotechnology company focused on regenerative medicine, from January 2020 to October 2022, in which role he was responsible for the Finance, Accounting, Investor Relations, and Corporate Communications departments. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a Japanese research-based human health care company that discovers, develops and markets products globally, from 2015 to 2018, in which role he was responsible for the Finance, Accounting, and Commercial Analytics groups as well as overseeing both Corporate and Commercial Compliance. Prior to joining Eisai, Mr. Macleod served as Vice President Finance – Merck Research Labs at Merck & Co., Inc., a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, from 2012 to 2015. Before joining Merck, Mr. Macleod served from 1998 to 2012 at F. Hoffmann-La Roche, Inc., a multinational health care company, in various roles, including as North American Chief Financial Officer from 2000 to 2011 as well as General Manager from 2010 to 2011. Mr. Macleod received his B.Sc. from St. Andrews University in Scotland and his M.B.A. from the University of Arizona. Mr. Macleod is a Certified Public Accountant licensed in Virginia.